AstraZeneca has recently established a new health-tech business called Evinova, which will leverage the company’s expertise in clinical trial design and study delivery. The goal of this venture is to offer scalable solutions to trial sponsors, clinical research organizations, care teams, and patients.

Evinova’s offerings will include advanced data collection techniques and machine learning algorithms to support teams in designing their studies. By doing so, the company aims to reduce the time and cost of developing new medicines, bring care closer to home for patients, and lessen the burden on healthcare systems. The company has announced major collaborations with clinical research organizations Parexel and Fortrea to expand the reach of Evinova’s digital health solutions to a broader customer base.

AstraZeneca’s CEO, Pascal Soriot, expressed his confidence in Evinova’s potential to have a significant impact on patient care, healthcare transformation, and carbon emissions reduction. The company also highlighted the expected growth of the digital health market, projecting it to be worth over $900 billion by 2032.

For more information about Evinova or any other queries related to AstraZeneca or health-tech industry news, contact Michael Susin at michael.susin@wsj.com.